Trial reportNature communications2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.
Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase III
In one paragraph
Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03150576 (Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.), which is not on this map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.
Who cites it
15 citing papers in PubMed.
- Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.Nature communications · 2025Trial
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Targeting the PARP10-BCAT2 axis disrupts branched-chain amino-acid metabolism to suppress bone metastasis in lung cancer.Cell death & disease · 2026Article
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Clinical Performance of International and Korean Genetic Testing Criteria for Hereditary Breast Cancer: A Large-Scale Cohort Analysis of 2,188 Individuals.Journal of breast cancer · 2026Article
- Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Literature Overview.Cancers · 2026Review
- Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.NPJ breast cancer · 2026Review
- Review
- Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration.Aging cell · 2026 · on this mapArticle
- UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer.ESMO real world data and digital oncology · 2026Article
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Multidimensional tumor heterogeneity and its role in therapeutic resistance.Frontiers in immunology · 2026Review
- Gene context drift identifies drug targets to mitigate cancer treatment resistance.Cancer cell · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Jean E AbrahamPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom. ja344@cam.ac.uk.ORCID http://orcid.org/0000-0003-0688-4807
Lenka Oplustil O'ConnorAstraZeneca, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0001-7580-1572
Louise GrybowiczCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Karen Pinilla AlbaPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-2723-0805
Alimu DayimuCambridge Clinical Trials Centre, Cancer Theme, University of Cambridge, Cambridge, United Kingdom.
Nikolaos DemirisDepartment of Statistics, Athens University of Economics and Business, Athens, Greece.
Caron HarveyCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Lynsey M DrewettRoyal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom.
Rebecca LuceyPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-6226-447X
Alexander FultonPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Anne N RobertsCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Joanna R WorleyPrecision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Ms Anita ChhabraCambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-9899-8010
Wendi QianCambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0002-4238-3471
Jessica BrownAstraZeneca, Cambridge, United Kingdom.
Richard HardyCambridge Clinical Trials Centre, Cancer Theme, University of Cambridge, Cambridge, United Kingdom.
Anne-Laure VallierCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Steve ChanThe City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Maria Esther Una CidonRoyal Bournemouth General Hospital, University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom.
Elizabeth SherwinIpswich Hospital, East Suffolk and North Essex NHS Foundation Trust, Ipswich, United Kingdom.
Amitabha ChakrabartiUniversity Hospitals Dorset NHS Foundation Trust, Poole, United Kingdom.
Claire SadlerApconix Ltd, Alderley Edge, Cheshire, United Kingdom.
Jen BarnesAstraZeneca, Cambridge, United Kingdom.
Mojca PersicUniversity Hospital of Derby and Burton, Derby, United Kingdom.
Sarah SmithBedford Hospital, Bedfordshire Hospitals NHS Foundation Trust, Bedford, United Kingdom.
Sanjay RajUniversity Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Annabel BorleyVelindre Cancer Centre, Cardiff, United Kingdom.
Jeremy P BraybrookeUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
Emma StaplesQueens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom.
Lucy C ScottBeatson West Of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom.
Cheryl A PalmerHinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, United Kingdom.
Margaret MoodyMacmillan Unit, West Suffolk Hospital NHS Foundation Trust, Bury St Edmunds, United Kingdom.
Mark J ChurnWorcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
Domenic PilgerAstraZeneca, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0001-7339-0685
Guido Zagnoli-VieiraAstraZeneca, Cambridge, United Kingdom.
Paul W G WijnhovenAstraZeneca, Cambridge, United Kingdom.
Mukesh B MukeshColchester General Hospital, East Suffolk & North Essex NHS Trust, Colchester, United Kingdom.
Rebecca R RoylanceUniversity College London Hospitals NHS Foundation Trust, London, United Kingdom.ORCID http://orcid.org/0000-0003-1453-6343
Philip C SchoutenDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Nicola C LevittOxford University Hospital NHS Foundation Trust, Oxford, United Kingdom.
Karen McAdamPeterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, United Kingdom.
Anne C ArmstrongThe Christie NHS Foundation Trust, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-0774-7006
Ellen R CopsonCancer Sciences Academic Unit, University of Southampton, Southampton, United Kingdom.
Emma McMurtryEMC2 Clinical Consultancy Ltd, Sale, United Kingdom.
Susan GalbraithAstraZeneca, Cambridge, United Kingdom.
Marc TischkowitzDepartment of Genomic Medicine, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-7880-0628
Elena ProvenzanoDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Mark J O'ConnorAstraZeneca, Cambridge, United Kingdom.ORCID http://orcid.org/0000-0003-1823-625X
Helena M EarlDepartment of Oncology, University of Cambridge, Cambridge, United Kingdom.
PARTNER Trial Group
Funding
AstraZeneca 1994-A093777Cancer Research UK (CRUK) CRUKE/14/048
Abstract
Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit DNA repair deficiency in germline BRCA1 and BRCA2 pathogenic variant (gBRCAm) cancers. Haematological toxicity limits chemotherapy-PARPi treatment combinations. In preclinical models we identified a schedule combining olaparib and carboplatin that avoids enhanced toxicity but maintains anti-tumour activity. We investigated this schedule in a neoadjuvant, phase II-III, randomised controlled trial for gBRCAm breast cancers (ClinicalTrials.gov ID:NCT03150576; PARTNER). The research arm included carboplatin (Area Under the Curve 5, 3-weekly); paclitaxel (80 mg/m
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAdultAgedCarboplatinFemaleHumansMiddle AgedNeoadjuvant TherapyPaclitaxelPhthalazinesPiperazinesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCarboplatinolaparibPaclitaxelPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03150576ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.